Here are the top 5 biosimilars articles for the week of July 6, 2020.
Number 5: The next stop in a long-running court battle between Sandoz and Amgen over a biosimilar etanercept could be the Supreme Court of the United States, after a federal court upheld 2 patents held by Amgen for its originator drug Enbrel.
Number 4: After a study from India suggested a higher incidence of adverse reactions in patients using biosimilar filgrastims, 2 European biosimilar consultants and oncologists raised objections to the study’s methodology.
Number 3: Rituximab was originally approved for treatment of non-Hodgkin lymphoma and has multiple additional approvals for orphan and nonorphan indications. But a recent study found off-label uses now account for more than half of patients receiving rituximab.
Number 2: In upholding a lower court ruling, a federal circuit court has decided that Amgen gave enough notice prior to launching its bevacizumab biosimilar. The court decision has frustrated an attempt by Genentech to block sales of the product.
Number 1: A pair of bipartisan senators introduced S 4134, a bill that aims to lower health care costs and increase access to biosimilars by instructing CMS to develop a shared savings model for biosimilars.
To read all of these articles and more, visit centerforbiosimilars.com.